The analysis revealed that the BPaL regimen is both more effective and cost-saving. For each additional Quality Adjusted Life Year (QALY) gained, the health system spends INR 379 less per patient compared to the standard regimen, indicating better health outcomes at lower costs.
Also Read:Delhi: 65,985 TB deaths in past 2 decades; 25-44 age group most affected
The BPaLM regimen was also found to be highly cost-effective, with an additional expenditure of only INR 37 per patient per additional QALY gained compared to the standard regimen. Both regimens were associated with lower or comparable overall healthcare costs, including medicines, hospital visits, and follow-up care.
MDR/RR-TB poses significant treatment challenges due to prolonged treatment duration, adverse effects, and higher costs. Shorter all-oral regimens can improve treatment adherence, reduce patient morbidity, and enable faster return to normal life, while also lowering the burden on the health system. The findings provide important economic evidence to support the use of shorter, all-oral regimens for MDR/RR-TB management in India. By reducing treatment duration from 9–18 months or longer to six months, these regimens align with national priorities to optimise resource utilisation and accelerate progress towards TB elimination.
The study concludes that BPaL-based regimens are likely to be cost-saving or highly cost-effective and may be considered for programmatic adoption under the NTEP to strengthen India’s response to drug-resistant TB. The full study can be accessed at: https://ijmr.org.in/cost-effectiveness.pdf
Also Read:Mission-Mode Approach for Drug Regulation and TB Mukt Bharat key priorities: JP Nadda
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.